Johnson & Johnson (JNJ)vsSynergy CHC Corp. Common Stock (SNYR)
JNJ
Johnson & Johnson
$227.19
-1.16%
HEALTHCARE · Cap: $547.28B
SNYR
Synergy CHC Corp. Common Stock
$0.32
+2.70%
HEALTHCARE · Cap: $4.52M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 317081% more annual revenue ($96.36B vs $30.38M). JNJ leads profitability with a 21.8% profit margin vs -40.6%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
SNYR
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-41.6%
Fair Value
$160.43
Current Price
$227.19
$66.76 premium
Margin of Safety
+57.5%
Fair Value
$3.88
Current Price
$0.32
$3.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
ROE of -361.1% — below average capital efficiency
Revenue declined 41.0%
Earnings declined 90.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : SNYR
The strongest argument for SNYR centers on Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SNYR
The primary concerns for SNYR are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SNYR is a turnaround play — different risk/reward profiles.
SNYR carries more volatility with a beta of 1.47 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 30/100), backed by strong 21.8% margins. SNYR offers better value entry with a 57.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Synergy CHC Corp. Common Stock
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Synergy CHC Corp. The company is headquartered in Westbrook, Maine.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?